Vanguard Portfolio Management
KROS icon

Vanguard Portfolio Management’s Keros Therapeutics KROS Stock Holding History

Vanguard Portfolio Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.98M Sell
652,635
-29,408
-4% -$328K ﹤0.01% 2321
2026
Q1 		$7.53M Buy
+682,043
New +$10.5M ﹤0.01% 2200

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Vanguard Portfolio Management's KROS Position: Q2 2026 in Review

Vanguard Portfolio Management reduced its Keros Therapeutics (KROS) stake by 4.3% in Q2 2026, selling an estimated $328K and leaving 652,635 shares worth $6.98M. The position accounts for ﹤0.01% of the portfolio, ranked #2321.

Vanguard Portfolio Management first reported a position in KROS in Q1 2026 and has held it in 2 quarters since. The position peaked at $7.53M in Q1 2026. 130 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Vanguard Portfolio Management held 652,635 shares of Keros Therapeutics worth $6.98M as of Q2 2026.
  • Vanguard Portfolio Management sold 29,408 Keros Therapeutics shares in Q2 2026, an estimated $328K.
  • Keros Therapeutics made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #2321 holding.
  • Vanguard Portfolio Management first reported a position in Keros Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Portfolio Management's Keros Therapeutics position peaked at $7.53M in Q1 2026.
  • 130 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.